London: Manose sugar, a nutritional supplement, can both slow tumor growth and enhance the effects of chemotherapy in multiple types of cancer, a study conducted in mice has found.
The study, published in the journal Nature, is a step to recognize how manosouse can be used to help cure cancer. Tumors use more glucose than normal, healthy tissue.
However, it is very difficult to control the amount of glucose in your body by diet alone.
The researchers at the University of Glasgow in the UK found that Manhose can interact with glucose to reduce the amount of sugar in diabetes.
"Tumors need a lot of glucose to grow, so limiting the amount they can use should slow cancer progression," said Professor Kevin Ryan of the University of Glasgow.
"The problem is that normal tissues need glucose as good, so we can not completely remove it from the body," said Ryan.
The study found a dosage of mananoes that could block enough glucose to slow tumor growth in mice, but not so much that normal tissues are affected.
"It is hosted by the fact that this is the perfect balance that, in the future, monomachus may be given to cancer patients to enhance chemotherapy without damaging their overall health," said Ryan.
The researchers first looked like mice with pancreatic, lung or skin cancer recall when mammosis was added to their drinking water and given as an oral treatment.
They found that adding the supplement significantly slowed the growth of tumors and did not cause any obvious side effect.
To test how manosous may also affect cancer treatment, mice are treated with cisplatin and doccorubicin – two of the most widely used chemotherapy drugs.
The researchers found that Manhose enhances the effects of chemotherapy, slowing tumor growth, reducing the number of tumors and even increasing the lives of some mice.
Some other types of cancer, including leukemia, osteosarcoma, ovarian and bowel cancer, are also invested.
Researchers increased cancer cells in the lab and then treated them with manose to see whether their growth was affected. Some cells responded well to the treatment, while others did not, they said.
It has also been found that the presence of an enzyme that breaks down the male in cells has been a good indicator of how effective treatment was.
"Our next step is to investigate what treatment only works in some cells so that we can work out what patients can benefit most of this approach," said Ryan.
"We hope to begin clinical trials with men and women in as soon as possible to determine its true potential as a new cancer therapy," he said.